Marker therapeutics awarded $2 million grant from nih in support of phase 1 study investigating mt-601 in car-relapsed patients with non-hodgkin's lymphoma

Marker therapeutics to receive non-dilutive funding from nih small business innovation research program based on preliminary clinical results and non-clinical data in lymphoma marker therapeutics to receive non-dilutive funding from nih small business innovation research program based on preliminary clinical results and non-clinical data in lymphoma
CAR Ratings Summary
CAR Quant Ranking